Creo Medical has provided a trading update for the 12-months to December 2022, noting revenues and EBITDA in-line with market expectations. Growth was delivered from core Creo products and technology revenues. Cash at year-end was c£13m with the company considering a number of financing options. Trained device user numbers continue to grow providing the foundation for future device revenue growth while first revenues have been recognised from Kamaptive licenses. Speedboat Slim was launched at th ....
